Abcam has appointed two additional Non-Executive Directors to its board: Timothy George Dye and Mark John Alexander Webster.
Tim Dye, age 43, is currently Chairman and Chief Executive of William Ransom & Son plc, an AIM quoted healthcare company, as well as being a director of Noble Troy Ltd. Over the past six years, and through a series of successful acquisitions, he has led the transformation of William Ransom into one of the UK’s largest natural healthcare groups. Prior to William Ransom, Tim built and ran privately held companies in automated meter reading, environmental management and property development.
Mark Webster, age 44, is a highly experienced pharmaceutical executive who has held senior management positions at Bayer, Shire Pharmaceuticals and Abbott Laboratories. Most recently he was Senior Vice President, Head of Global Strategic Marketing and Licensing / Acquisitions at Bayer Pharmaceuticals.
Commenting on today’s announcement, Jonathan Milner, Abcam’s Chief Executive Officer, said: “I am pleased to welcome both Tim and Mark to Abcam’s Board. Their experience, both in business and in the international pharmaceutical industry, will be of significant value to the Company as we continue to deliver our strategy of becoming the world’s leading research antibody supplier.”